Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Key facts
Counted staff
1
self-reported band not used
Founded
2016
10 years
Legal entities
None matched
Office countries
1
1 address
Funding rounds
None on record
Company type
Educational
self-reported
Description
CRE RESPOND is a $2.5 million multi-institutional collaborative funded by the National Health and Medical Research Council of Australia from 2021 – 2026 to reduce the burden of antimicrobial resistance through optimal personalised dosing. It aims to bring about new findings from research and share these with clinicians so that they can provide better treatment to their patients and improve outcomes for them and their families.
Infection causes unacceptably high morbidity and mortality worldwide. It is common for Australian clinicians to be confronted by patients who are infected by pathogens that are resistant to all available antimicrobials.
CRE RESPOND will address antimicrobial resistance and unacceptably poor patient outcomes with evidence-based personalised antimicrobial drug dosing.
The CRE will achieve this through a large body of work to generate new knowledge that will change policy and practice to improve patient and health system outcomes and build research capacity to make further gains in personalizing dosing and reducing antimicrobial resistance.
CRE RESPOND aims to:
-Generate new knowledge that leads to improved health outcomes -Promote effective transfer of research outcomes into health policy and/or practice -Develop the health and medical research workforce by providing opportunities to advance the training of new researchers, particularly those with a capacity for independent research and future leadership roles -Facilitate collaboration
Specialties
All 26 specialties
- Infectious diseases
- Pharmacokinetics
- Antimicrobial Optimisation
- Research
- Pharmaceuticals
- Personalised medicine
- Therapeutics
- Critical care medicine
- Antimicrobial resistance
- Antibiotics
- Antifungals
- Antivirals
- Respiratory medicine
- Bioanalysis
- Burns patients
- Transplant medicine
- Antibiotic administration
- Drug monitoring
- Dose personalisation
- Clinical practice guidelines
- Clinical trials
- Clinical research
- Pharmacometric analysis
- Microsampling
- Therapeutic drug monitoring
- Clinical dosing
Locations
Country footprint
Show as table · Offices in 1 country
| Countries | 1 |
|---|---|
| Primary country | AU |
All codes: AU
Addresses
- AUUQ CCR; Herston, QLD 4006Primary
Grid intelligence Members
Signals & hiring
Hiring, headcount and registry-change signals, streamed to members.
Latest signal
Hiring activity
Headcount trend
Financials
Registry-filed capital and financial indicators, standardised by TheGrid.
Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss
People & contacts
1 employee profiles on record · names withheld.
Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.
The people relation is never requested, so there is nothing here to unlock.
FAQ
How many people work at CRE RESPOND?
1 counted staff profiles at January 2026. The brand's self-reported band sits above that count and is not published as a headcount.
Where does CRE RESPOND have offices?
One address on record, Australia only. Primary: UQ CCR, Herston, QLD 4006.
Has CRE RESPOND raised funding?
None linked to this brand.
What does CRE RESPOND list as its specialties?
26 tags on the brand's own list, among them clinical trials, clinical research and research.
Which companies are listed alongside CRE RESPOND?
Eight peer profiles on record: Pelvic Pain Foundation of Australia and Jetra Therapeutics.